



Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 42571

Manuscript Type: EDITORIAL

Role of cenicriviroc in the management of nonalcoholic fatty liver disease

Georgios Neokosmidis, Konstantinos Tziomalos

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease in high-income countries and is associated with increased morbidity and mortality. Macrophages appear to play an important role in the development and progression of hepatic fibrosis in patients with NAFLD.

Match Overview

| | | |
|---|--|----|
| 1 | Internet 53 words crawled on 10-Apr-2018 eprints.nottingham.ac.uk | 4% |
| 2 | Crossref 53 words Annie J. Kruger, Bryan C. Fuchs, Ricard Masia, Jacinta A. Holmes et al. "Prolonged cenicriviroc therapy reduces | 4% |
| 3 | Publications 22 words "Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at t", Busi | 2% |
| 4 | Crossref 16 words Monica A. Konerman, Stephen A. Harrison. "Overview of Clinical Treatment Trials for NASH", <i>Current Hepatology</i> | 1% |
| 5 | Crossref 15 words Ju, Cynthia, and Frank Tacke. "Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to | 1% |
| 6 | Internet 14 words crawled on 06-Aug-2018 ejnmires.springeropen.com | 1% |
| 7 | Internet 14 words crawled on 25-Dec-2017 | 1% |

找到约 71,700 条结果 (用时 0.55 秒)

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver ...

<https://www.ncbi.nlm.nih.gov/pubmed/29448843> - 翻译此页

作者: F Tacke - 2018 - 被引用次数: 4 - 相关文章

2018年2月22日 - INTRODUCTION: **Nonalcoholic fatty liver disease** (NAFLD) has an increasing prevalence worldwide. At present, no specific pharmacotherapy ...

Treatment of Nonalcoholic Fatty Liver Disease: Where do we Stand ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817303/> - 翻译此页

作者: A Dajani - 2016 - 被引用次数: 13 - 相关文章

跳到POSSIBLE ROLE FOR THE RENIN-ANGIOTENSIN SYSTEM - Hepatic **steatosis** and fibrosis, improved in seven out of the ... the gut to the **liver** has an important **role** in the pathogenesis ...

Cenicriviroc CVC is a dual inhibitor of the ...

Management of nonalcoholic fatty liver disease: Lessons learned from ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1195> - 翻译此页

作者: N Alkhouiri - 2018 - 相关文章

2018年6月7日 - **Nonalcoholic fatty liver disease** (NAFLD) is considered the hepatic manifestation of ... CVC; **cenicriviroc**; FDA; U.S. Food and Drug **Administration**; HCC ... of liver injury, indicating a potential **role** in the **treatment** of NAFLD.17 ...

AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the ...

<https://clinicaltrials.gov/ct2/show/NCT03028740> - 翻译此页

2017年1月23日 - It identifies **the role** of the intervention that participants receive. Nonalcoholic Steatohepatitis, Drug: **Cenicriviroc** Drug: Placebo, Phase 3 ... for the **Treatment** of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. Experimental Drug: **Cenicriviroc** Non-

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 35,400 条结果 (用时 0.46 秒)

Google 学术 : Role of cenicriviroc in the management of nonalcoholic fatty liver disease

Global epidemiology of nonalcoholic fatty liver disease ... - Younossi - 被引用次数 : 1045

... predictors of liver fibrosis in patients with nonalcoholic ... - Angulo - 被引用次数 : 1789

Fatty liver hepatitis (steatohepatitis) and obesity: an ... - Wanless - 被引用次数 : 1424

Pharmacological management of nonalcoholic fatty liver disease ...

<https://www.sciencedirect.com/science/article/pii/S0026049516300087> - 翻译此页

作者 : D Barb - 2016 - 被引用次数 : 44 - 相关文章

Nonalcoholic fatty liver disease (NAFLD) affects one-third of the population and ... management of diabetes and cardiovascular risk factors, although the role of that is a dual chemokine receptor (CCR) 5 and 2 antagonist (cenicriviroc).

Management of nonalcoholic fatty liver disease: Lessons learned from ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049065/> - 翻译此页

作者 : N Alkhoury - 2018 - 被引用次数 : 2 - 相关文章

2018年6月7日 - Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic ... a role in NAFLD development and progression are being developed at a rapid pace. ... CVC: cenicriviroc; FDA: U.S. Food and Drug Administration; HCC ...

Current and future pharmacologic treatment of nonalcoholic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491795/> - 翻译此页

作者 : BA Banini - 2017 - 被引用次数 : 16 - 相关文章

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 83,100 条结果 (用时 0.59 秒)

Google 学术: Role of cenicriviroc in the management of nonalcoholic fatty liver disease

Global epidemiology of **nonalcoholic fatty liver disease** ... - Younossi - 被引用次数: 1045

... predictors of **liver fibrosis** in patients with **nonalcoholic** ... - Angulo - 被引用次数: 1789

Fatty liver hepatitis (steatohepatitis) and obesity: an ... - Wanless - 被引用次数: 1424

Management of nonalcoholic fatty liver disease: Lessons learned from ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049065/> - 翻译此页

作者: N Alkhoury - 2018 - 被引用次数: 2 - 相关文章

2018年6月7日 - **Nonalcoholic fatty liver disease** (NAFLD) is considered the hepatic ... a **role** in NAFLD development and progression are being developed at a rapid pace. ... CVC: **cenicriviroc**; FDA: U.S. Food and Drug Administration; HCC ...

Current and future pharmacologic treatment of nonalcoholic ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491795/> - 翻译此页

作者: BA Banini - 2017 - 被引用次数: 16 - 相关文章

This review presents the agents currently used in **managing** NAFLD and their ... Keywords: chronic liver disease, cirrhosis, fibrosis, **nonalcoholic fatty liver disease**, An ongoing phase 2a study of **cenicriviroc** (ORION) is aimed at assessing the This important study (FLINT trial) established the **role** of FXR in NASH by ...

Pharmacological management of nonalcoholic fatty liver disease ...

<https://www.sciencedirect.com/science/article/pii/S0026049516300087> - 翻译此页

作者: D Barb - 2016 - 被引用次数: 44 - 相关文章

Nonalcoholic fatty liver disease (NAFLD) affects one-third of the population and ... **management** of diabetes and cardiovascular risk factors, although the **role** of that is a dual chemokine receptor (CCR) 5 and 2 antagonist (**cenicriviroc**).

Efficacy and safety study of cenicriviroc for the treatment of non ...

<https://www.sciencedirect.com/science/article/pii/S155171441630026X> - 翻译此页